Intranasal Vaccine Developed
According to a study from the University of Houston, researchers have made a vaccine breakthrough by developing an “intranasal vaccine” that has shown to provide immunity to Covid-19. Part of the draw for this type of vaccine is that it is non-invasive and does not require a shot like the vaccines we know now.
A benefit to these vaccines is that they are designed to elicit mucosal immunity. Mucosal immunity being the immune system responding at sites of our body that interact with the external environment, like our respiratory system.
The team responsible for these vaccines are working on plans for global distribution and say that the vaccines need to be stable and easily shipped. The components of the vaccine, “the protein (lyophilized) and the adjuvant (NanoSTING) are stable for over 11 months and can be stored and shipped without the need for freezing.”
For more updates be sure to check back with the ABN Blog regularly